Circulation Reports最新文献

{"title":"Effect of Constant vs. Variable Moderate-Intensity Load on Peak Oxygen Uptake in Outpatient Cardiac Rehabilitation.","authors":"Hajime Saeki, Miho Kuramoto, Yoshinori Iida, Kaori Yasumura, Yoh Arita, Nobuyuki Ogasawara","doi":"10.1253/circrep.CR-23-0024","DOIUrl":"10.1253/circrep.CR-23-0024","url":null,"abstract":"<p><p><b><i>Background:</i></b> In outpatient center-based cardiac rehabilitation (O-CBCR), moderate-intensity continuous training (MICT) based on the anaerobic threshold (AT) determined by cardiopulmonary exercise stress testing is recommended. However, it is unclear whether differences in exercise intensity within the MICT domain affect peak oxygen uptake (%peakV̇O₂). <b><i>Methods and Results:</i></b> We retrospectively evaluated patients who underwent O-CBCR at Japan Community Healthcare Organization Osaka Hospital. Those treated with the constant-load method were designated as Group A (n=38), whereas those treated with the variable-load method were designated as Group B (n=48). Although the change in exercise intensity was significantly greater in Group B by approximately 4.5 W, the change in %peakV̇O₂ was not significantly different between groups. Group A had a significantly longer exercise time than Group B (by approximately 4-5 min). No deaths or hospitalizations occurred in either group. The percentage of episodes with exercise cessation was similar between the 2 groups, but the percentage of episodes with load reduction was significantly higher in Group B, mostly because of the increased heart rate. <b><i>Conclusions:</i></b> In supervised MICT based on AT, the variable-load method increased exercise intensity more than the constant-load method without severe complications, but did not improve %peakV̇O₂.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 5","pages":"167-176"},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6f/63/circrep-5-167.PMC10166670.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9467651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare Case of Acute Closed Type B Aortic Dissection Complicated by Giant Left Subclavian Artery Aneurysm.","authors":"Masashi Yanagisawa,&nbsp;Naoki Fujimoto,&nbsp;Satoshi Fujita,&nbsp;Takatoshi Higashigawa,&nbsp;Yu Shomura,&nbsp;Kaoru Dohi","doi":"10.1253/circrep.CR-23-0010","DOIUrl":"10.1253/circrep.CR-23-0010","url":null,"abstract":"","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 5","pages":"225-226"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/79/circrep-5-225.PMC10166663.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9832895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impacts of CHADS₂, CHA₂DS₂-VASc, and CHA₂DS₂-VASc-HS Scores on Clinical Outcomes After Elective Drug-Eluting Stent Placement for De Novo Coronary Stenosis.","authors":"Tomoaki Ukaji, Tetsuya Ishikawa, Hidehiko Nakamura, Yukiko Mizutani, Kouta Yamada, Masatoshi Shimura, Yuki Kondo, Yohei Tamura, Yuri Koshikawa, Itaru Hisauchi, Shiro Nakahara, Yuji Itabashi, Sayuki Kobayashi, Isao Taguchi","doi":"10.1253/circrep.CR-22-0120","DOIUrl":"10.1253/circrep.CR-22-0120","url":null,"abstract":"<p><p><b><i>Background:</i></b> The prognostic impact of CHADS₂, CHA₂DS₂-VASc, and CHA₂DS₂-VASc-HS scores on clinical outcomes after drug-eluting stent (DES) placement has not been fully elucidated. <b><i>Methods and Results:</i></b> The present study was a retrospective, non-randomized, single-center, and lesion-based study. Target lesion failure (TLF), comprising cardiac death, non-fatal myocardial infarction, and target vessel revascularization, occurred in 7.1% of 872 consecutive de novo coronary lesions in 586 patients. These patients were electively and exclusively treated by DESs from January 2016 to January 2022 until July 2022 with a mean (±SD) observational interval of 411±438 days. Multivariate Cox proportional hazard analysis revealed that CHA₂DS₂-VASc-HS scores ≥7 (hazard ratio [HR] 1.800; 95% CI 1.06-3.05; P=0.029) was a significant predictor of cumulative TLF among 24 variables evaluated. CHADS₂ scores ≥2 (HR 3.213; 95% CI 1.32-7.80; P=0.010) and CHA₂DS₂-VASc scores ≥5 (HR 1.980; 95% CI 1.10-3.55; P=0.022) were also significant in the multivariate analysis. Pairwise comparisons of receiver operating characteristic curves for CHADS₂ score ≥2, CHA₂DS₂-VASc score ≥5, and CHA₂DS₂-VASc-HS score ≥7 showed they were equivalent in terms of predicting the incidence of TLF, with areas under the curve of 0.568, 0.575, and 0.573, respectively. <b><i>Conclusions:</i></b> All 3 cardiocerebrovascular thromboembolism risk scores were strong predictors of the incidence of cumulative mid-term TLF after elective DES placement, with cut-off values of 2, 5, and 7, respectively, and equivalent prognostic impacts.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 4","pages":"123-132"},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/fa/circrep-5-123.PMC10072895.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9272045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Pulmonary Valve Endocarditis by Electrocardiography-Gated Cardiac Computed Tomography.","authors":"Sayaka Funabashi,&nbsp;Takashi Kohno,&nbsp;Takato Mohri,&nbsp;Shinsuke Takeuchi,&nbsp;Toshinori Minamishima,&nbsp;Kenichi Yokoyama","doi":"10.1253/circrep.CR-23-0006","DOIUrl":"https://doi.org/10.1253/circrep.CR-23-0006","url":null,"abstract":"case of IE in the pulmonary valve that was detected by electrocardiography-gated cardiac computed tomography (CT). A 58-year-old man with a history of atopic dermatitis presented with sepsis. Blood cultures indicated the presI solated pulmonary valve endocarditis is a rare type of right-sided infective endocarditis (IE).1 Diagnosis of isolated pulmonary valve endocarditis is difficult using transthoracic and transesophageal echocardiography (TTE and TEE, respectively). Herein, we report a","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"99-100"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/ee/circrep-5-99.PMC9992499.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9095558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Expanding Hematoma in Device Pocket Developing 5 Years After Implantation.","authors":"Tomoyuki Uchida,&nbsp;Hironori Ishiguchi,&nbsp;Toru Ariyoshi,&nbsp;Miho Fujita,&nbsp;Masakazu Fukuda,&nbsp;Yasuaki Wada,&nbsp;Yasuhiro Yoshiga,&nbsp;Takayuki Okamura,&nbsp;Masafumi Yano","doi":"10.1253/circrep.CR-22-0128","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0128","url":null,"abstract":"","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"95-96"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6c/5e/circrep-5-95.PMC9992505.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9444930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing.","authors":"Michihiro Suwa,&nbsp;Yuki Nohara,&nbsp;Isao Morii,&nbsp;Masaya Kino","doi":"10.1253/circrep.CR-22-0076","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0076","url":null,"abstract":"<p><p><b><i>Background:</i></b> Off-label dosing of direct oral anticoagulants (DOAC) as a treatment for non-valvular atrial fibrillation (NVAF) is problematic. Here, we investigated the status of rivaroxaban and edoxaban dosing by monitoring plasma concentrations (PCs). <b><i>Methods and Results:</i></b> We monitored drug PCs in 391 and 333 outpatients receiving rivaroxaban and edoxaban, respectively, for NVAF. Drug doses were adjusted if the PC was above the cut-off value (rivaroxaban: 404 ng/mL; edoxaban: 402 ng/mL), determined from receiver operating characteristic curves for predicting bleeding events. On-label standard dosing was reduced to off-label underdosing due to high PCs above the cut-off more often for rivaroxaban (28.1%) than edoxaban (12.6%; P<0.001). Over a median follow-up of 13 months for rivaroxaban and 10 months for edoxaban, the annual incidence of bleeding events was higher with rivaroxaban than with edoxaban (4.88 vs. 3.73 patient-years; P<0.05), although no thromboembolic events occurred in either group. Furthermore, for patients with creatinine clearance >50 mL/min and body weight ≤60 kg, there was a greater incidence of bleeding events with rivaroxaban on-label 15 mg dosing than with edoxaban on-label 30 mg dosing (22.2% vs 2.9%; P<0.01). <b><i>Conclusions:</i></b> Monitoring the PCs of rivaroxaban and edoxaban in NVAF patients enables dose adjustments to reduce bleeding risk. The incidence of bleeding under drug PC monitoring was less in the edoxaban than rivaroxaban group.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"80-89"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/e2/circrep-5-80.PMC9992501.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10195115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CORRIGENDUM: Deterioration of Phosphate Homeostasis Is a Trigger for Cardiac Afterload　- Clinical Importance of Fibroblast Growth Factor 23 for Accelerated Aging.","authors":"Yuji Mizuno,&nbsp;Toshifumi Ishida,&nbsp;Fumihito Kugimiya,&nbsp;Seiko Takai,&nbsp;Yoshiharu Nakayama,&nbsp;Koichiro Yonemitsu,&nbsp;Eisaku Harada","doi":"10.1253/circrep.CR-66-0011","DOIUrl":"https://doi.org/10.1253/circrep.CR-66-0011","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1253/circrep.CR-22-0124.].</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"103-104"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/99/circrep-5-103.PMC9992500.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9444931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery.","authors":"Kotaro Horie,&nbsp;Teruhiko Imamura","doi":"10.1253/circrep.CR-23-0002","DOIUrl":"https://doi.org/10.1253/circrep.CR-23-0002","url":null,"abstract":"collecting duct.3 It may be of great interest to investigate other predictors that are associated with the achievement of the primary endpoint in the study of Matsuda et al. The optimal timing to initiate tolvaptan is another concern. Matsuda et al initiated tolvaptan on postoperative Day 2. Earlier initiation of tolvaptan orally or intravenously may have more clinical benefit by increasing urine volume and maintaining renal function.4","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"101"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/33/circrep-5-101.PMC9992502.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9095557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery　- Reply.","authors":"Yasuhiro Matsuda,&nbsp;Tadaaki Koyama","doi":"10.1253/circrep.CR-23-0014","DOIUrl":"https://doi.org/10.1253/circrep.CR-23-0014","url":null,"abstract":"predictor of the response to tolvaptan.6 In future, if possible, we would like to conduct a comparative study in a group of patients with poor renal function. However there is a high possibility that this group of patients will be treated with a combination of multiple drugs, such as other diuretics and carperitide, and it will therefore be difficult to evaluate the effects of tolvaptan alone.","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"102"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/2b/circrep-5-102.PMC9992506.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Rehabilitation for Patients With Stable Ischemic Heart Disease Without Revascularization　- Rationale and Design of a Single-Arm Pilot Study.","authors":"Tomotsugu Seki,&nbsp;Makoto Murata,&nbsp;Kensuke Takabayashi,&nbsp;Takashi Yanagisawa,&nbsp;Masayuki Ogihara,&nbsp;Ritsuko Kurimoto,&nbsp;Keisuke Kida,&nbsp;Koichi Tamita,&nbsp;Xiaoyang Song,&nbsp;Neiko Ozasa,&nbsp;Ryoji Taniguchi,&nbsp;Miho Nishitani-Yokoyama,&nbsp;Shinji Koba,&nbsp;Ryosuke Murai,&nbsp;Yutaka Furukawa,&nbsp;Maki Hamasaki,&nbsp;Hirokazu Kondo,&nbsp;Hironori Hayashi,&nbsp;Asako Ootakara-Katsume,&nbsp;Kento Tateishi,&nbsp;Satoaki Matoba,&nbsp;Hitoshi Adachi,&nbsp;Hirokazu Shiraishi","doi":"10.1253/circrep.CR-22-0131","DOIUrl":"https://doi.org/10.1253/circrep.CR-22-0131","url":null,"abstract":"<p><p><b><i>Background:</i></b> Clinical practice guidelines strongly recommend optimal medical therapy (OMT), including lifestyle modification, pharmacotherapy, and exercise-based cardiac rehabilitation (CR), in patients with stable ischemic heart disease (SIHD). However, the efficacy and safety of CR in patients with SIHD without revascularization remain unclear. <b><i>Methods and Results:</i></b> The Prospective Registry of STable Angina RehabiliTation (Pre-START) study is a multicenter, prospective, single-arm, open-label pilot study to evaluate the efficacy and safety of CR on health-related quality of life (HRQL), exercise capacity, and clinical outcomes in Japanese patients with SIHD without revascularization. In this study, all patients will undergo guideline-based OMT and are encouraged to have 36 outpatient CR sessions within 5 months after enrollment. The primary endpoint is the change in the Seattle Angina Questionnaire-7 summary score between baseline and the 6-month visit; an improvement of ≥5 points will be defined as a clinically important change. Secondary endpoints include changes in other HRQL scores and exercise capacity between baseline and the 6-month visit, as well as clinical outcomes between enrollment and the 6-month visit. <b><i>Conclusions:</i></b> The Pre-START study will provide valuable evidence to elucidate the efficacy and safety of CR in patients with SIHD and indispensable information for a subsequent randomized controlled trial. The study was registered with the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (ID: UMIN000045415) on April 1, 2022.</p>","PeriodicalId":10276,"journal":{"name":"Circulation Reports","volume":"5 3","pages":"90-94"},"PeriodicalIF":0.0,"publicationDate":"2023-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/44/circrep-5-90.PMC9992498.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9095556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}